Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on rare diseases, with a political profile defined by concentrated congressional selling activity from a single member and no direct lobbying or federal contract footprint.
BusinessWhat INSM does
Insmed is a global biopharmaceutical company developing and commercializing therapies for patients with serious and rare diseases. Its revenue is derived from the sale of its approved products, primarily in the respiratory disease space, with a pipeline targeting unmet medical needs. The company operates in a highly regulated environment governed by the FDA and international health authorities.
12 months past · 3 months futureINSM activity timeline
Lifetime Government AwardsINSM federal contracts
INSM doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding INSM
Politicians Trading INSMMembers of Congress with recent INSM positions
Congressional TradesWho in Congress is trading INSM
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting INSMLive legislation impacting this stock
Political ProfileWhere INSM sits in Washington
[object Object]
STRUCTURAL: No lobbying spend (`get_political_influence.lobbying.total_income`: $0), no federal contracts (`get_government_precedent.federal_contracts_summary`: null), and no political donations. EVIDENTIARY: Concentrated selling by a single congressman (Rep. Crenshaw, 4 sale events) outweighs a single, smaller purchase by another. Net: Evidentiary signal from repeated congressional sales points to bearish sentiment among informed political actors.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Broad legislative impact from multiple pending healthcare billsU.S. Congress"`Recent bill_impacts` lists 8 healthcare bills with estimated revenue impacts ranging from $3.19M to $6.06M."
Regulatory opportunities
- No specific regulatory opportunities flagged.
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
Live signals + predictions for INSM — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades INSM
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord